Get the Stockscreener App
4.85
31.44%
1.16
Pre-market:
4.90
0.05
+1.03%
Puma Biotechnology Inc stock is traded at $4.85, with a volume of 3.94M.
It is up +31.44% in the last 24 hours and up +43.07% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$3.69
Open:
$3.72
24h Volume:
3.94M
Relative Volume:
9.17
Market Cap:
$244.30M
Revenue:
$230.47M
Net Income/Loss:
$30.28M
P/E Ratio:
7.9508
EPS:
0.61
Net Cash Flow:
$38.86M
1W Performance:
+52.52%
1M Performance:
+43.07%
6M Performance:
+75.72%
1Y Performance:
+28.99%
1-Day Range:
$3.71
$5.06
1-Week Range:
$3.045
$5.06
52-Week Range:
$2.225
$5.06
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
4.85 | 183.16M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma Biotechnology shares get favourable price bump on strong Q2 results - Mugglehead Magazine
10 Most Undervalued Biotech Stocks to Buy Now - Insider Monkey
Why is Puma Biotechnology Inc. stock going downStock Picks with Accelerated Return - kangso.co.kr
Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Yahoo Finance
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - MSN
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript - Insider Monkey
Puma Biotechnology 2025 Q2 Earnings Profitability Returns with 229.3% Net Income Surge - AInvest
Puma Biotechnology's Q2 Earnings Outperformance and Nerlynx Momentum Signal a Strategic Buy Opportunity - AInvest
Puma Biotechnology Awards Nearly 28,000 Shares to Three New Employees Under Nasdaq Rule - Stock Titan
Puma Biotechnology Q2 2025 slides: NERLYNX revenue grows 14% quarter-over-quarter - Investing.com India
Earnings call transcript: Puma Biotechnology beats Q2 2025 earnings forecast - Investing.com
Puma Biotechnology Flips To Profit On Cancer Drug Sales - Finimize
Puma Biotechnology Inc (PBYI) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Puma Biotechnology 2025 Q2 Earnings Strong Performance as Net Income Surges 229.3% - AInvest
Puma anticipates $192M–$198M NERLYNX revenue for 2025 as company advances alisertib trials - MSN
Puma Biotechnology Reports Second Quarter 2025 Financial Results - BioSpace
Puma Biotechnology Reports Strong Q2 2025 Results - TipRanks
Puma Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Puma Biotechnology: Hold Rating Amid Stable Q2 Performance and Uncertain Trial Outcomes - TipRanks
Puma Biotechnology Anticipates $192M-$198M NERLYNX Revenue for 2025 Amid Alisertib Trials Advancement - AInvest
Puma Biotechnology's Q2 2025: Key Contradictions in Alisertib Strategy, In-Licensing, and Sales Growth - AInvest
Puma Biotech: Q2 Earnings Snapshot - San Francisco Chronicle
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Puma Biotechnology files Form 8-K regarding Q2 2025 results - Stock Titan
Puma Biotechnology Reports Second Quarter Financial Results - Yahoo Finance
Screener Results Flag Puma Biotechnology Inc. as OversoldGrowth Based Investment Plan Guidance Highlighted - metal.it
What are the latest earnings results for Puma Biotechnology Inc.Get professional advice for portfolio optimization - Jammu Links News
How volatile is Puma Biotechnology Inc. stock compared to the marketInvest in high-yield stocks with confidence - Jammu Links News
What drives Puma Biotechnology Inc. stock priceDiscover high-impact stocks for growth - Jammu Links News
How strong is Puma Biotechnology Inc. company’s balance sheetAchieve consistent profits with proven methods - Jammu Links News
What are analysts’ price targets for Puma Biotechnology Inc. in the next 12 monthsFree Market Volatility Navigation Tips - Jammu Links News
What makes Puma Biotechnology Inc. stock price move sharplyOutstanding capital growth - Jammu Links News
What catalysts could drive Puma Biotechnology Inc. stock higher in 2025Tremendous wealth creation - Jammu Links News
Is Puma Biotechnology Inc. a good long term investmentStay ahead with daily market updates - Jammu Links News
What analysts say about Puma Biotechnology Inc. stockInvest confidently with professional market insights - Jammu Links News
What are Puma Biotechnology Inc. company’s key revenue driversUnlock powerful portfolio optimization tools - Jammu Links News
What is the dividend policy of Puma Biotechnology Inc. stockRobust financial gains - Jammu Links News
Is Puma Biotechnology Inc. stock overvalued or undervaluedDiscover market opportunities with expert help - Jammu Links News
Puma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years ago - Yahoo Finance
Puma Biotechnology's Share Price Tanks 70% Over Five Years Despite Becoming Profitable. - AInvest
Volatility clustering patterns for Puma Biotechnology Inc.Daily Breakout List with Smart Filters - Newser
How sentiment analysis helps forecast Puma Biotechnology Inc.Free Fast Entry High Potential Stock Alerts - Newser
How to monitor Puma Biotechnology Inc. with trend dashboardsShort-Term Stock Trend Forecast Guide - Newser
How to use a screener to detect Puma Biotechnology Inc. breakoutsAI Stock Movement Forecast with Accuracy - Newser
Does Puma Biotechnology Inc. stock pay reliable dividendsBeginner Friendly Stock Selection Guide Updated - metal.it
Why Puma Biotechnology Inc. stock attracts strong analyst attentionEarly Entry Tips With Low Risk Zone Shared - metal.it
Predicting Puma Biotechnology Inc. trend using moving averagesWeekly Trend Watch with Market Signals - Newser
Can volume confirm reversal in Puma Biotechnology Inc.Daily Market Momentum Summary and Strategy - Newser
Signal strength of Puma Biotechnology Inc. stock in tech scannersFree Safe Entry Stock Watch Suggestions - Newser
Puma Biotechnology Inc. stock trend forecastTop Stock Picks with Forecast Accuracy - Newser
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):